| ²é¿´: 2994 | »Ø¸´: 1 | ||
pxiao08Ìú³æ (³õÈëÎÄ̳)
|
[ÇóÖú]
½ô¼±ÇóÖú£¡ÎÄÕÂacceptºóÌîд·¢±íͬÒâÊ飨PUBLISHING AGREEMENT£©µÄÎÊÌâ
|
|
¸÷λվÓÑ£¬±¾ÈËͶ¸åÁËһƪSAGEÆìÏÂÆÚ¿¯£¬ÏÖÒÑACCEPTED¡£ÔÚÌîдJOURNAL CONTRIBUTOR'S PUBLISHING AGREEMENT¹ý³ÌÖгöÏÖÁËһЩ¸öÈ˲»Àí½âµÄÎÊÌ⣬Çë¸÷λ´Í½Ì¡£²»Ê¤¸Ðл£¡£¡£¡ 2. Declaration of Conflict of Interest and Financial Disclosure: Contributors certify that the answers below are a thorough and accurate representation of all potential conflicts of interest of each Contributor and disclosure of full and complete financial support information relating to the Contribution: 1. The Contributors, either individually or collectively, have received financial support, including pharmaceutical company support, authorship or promotion of the Contribution. Yes No In the box provided, enter a list and description of all forms and sources of financial support that each Contributor received related to the Contribution, including for each Contributor: a) the name of the supporting organization, b) the interests it represents and/or its product discussed or alluded to within the Contribution, and c) all Contributors who received support: ÎÊÌâ1. ÊÇÒªÌî»ù½ð×ÊÖúÏîÄ¿Â𣿱ÈÈç×ÔÈ»¿ÆÑ§»ù½ð×ÊÖúÁ˱¾Ñо¿£¨ÎÒͶ¸åµÄ¸½¼þÀïҲдÁË£©£¬ÕâÀﻹҪдÂ𣿠ÎÊÌâ2. Èç¹ûÒªÌîдµÄ»°£¬ÊÇÌîÔÚËüÒªÇóµÄ¿òÀÄÚÈÝÔõôÌîÄØ£¿Êǰ´ÕÕÏÂÃæµÄ¸ñʽÂ𣿠a£¬Õⲿ·ÖÊÇÌî ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð£¿ b£¬Õⲿ·ÖÔõôÌîÄØ£¿ÊÇÌîдNo potential conflict of interest relevant to this articleÂ𣿠c£¬Õⲿ·ÖÊÇÕâÑùÌîÂð£¿xx£¨±ÈÈçÎÒ£©received ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðµÄ×ÊÖú¡£ÉÏÃæÕâ¸ö²¿·Ö 2. The Contributors, either individually or collectively, have commercial or financial involvements that might present an appearance of a conflict of interest related to the Contribution. Yes No In the box provided, enter a list and description of all forms of commercial or financial involvements of each Contributor who received support: ÎÒÕâÆªÎÄÕÂÖ»ÊÇÊܵ½Èç¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðºÍÎÒÃÇѧУ»ù½ðµÄ×ÊÖú£¬ÄÇôÕⲿ·ÖÔõôÌîÄØ£¿¿ÉÄܻᵼÖÂ·ÖÆçµÄÉÌÒµ»ò²ÆÕþ×ÊÖú£¿ÊÇʲôÒâ˼£¿ 3. Contributors, either individually or collectively, have signed agreements with sponsors of the research reported in the Contribution that places any requirements on their publication of the research findings, such as preventing them from publishing both positive and negative results or that forbids them from publishing the research without the prior approval of the sponsor. Yes No In the box provided, enter a list and description of all sponsor agreements for each Contributor, including a description of any publication requirements:Õⲿ·ÖÊÇÒªÌîÊ²Ã´ÄØ£¿ÊDz»ÊÇһЩҩÎïÊÔÑéµÄÑо¿²ÅÒªÌîÐ´ÄØ£¿£¨ÑôÐÔÒõÐÔ½á¹û£¬Ò©³§²»È÷¢²¼£©ÎÒÕâÆªÎÄÕºÃÏñ²»Éæ¼°µ½Õâ¸ö·½Ã棬¾ÍÊÇÒ»¸öÁ÷Ðв¡Ñ§µÄµ÷²é¡£ Çë¸÷λսÓÑÖ¸µã£¡ xxÔÓÖ¾ reserves the right to include any information provided by Contributors in the sections above within the published Contribution as part of the Financial Disclosure Statement. If no conflicts of interest are declared, then the following statement may be printed with the Contribution: ¡®The Authors declared that they had no conflicts of interests in their authorship and publication of this Contribution.¡¯ Õâ¾ä»°Ð´ÔÚÕâÀïÊÇʲôÒâ˼£¿Ã»ÓÐÀûÒæÕùÒ飬¾Í»áÔÚÎÄÕÂÖгöÏÖ¡°×÷ÕßÐû´«Ã»ÓÐÀûÒæÕùÒ顱£¿ 3. Additional Items: 1. The Contribution contains third party material requiring permission. (Please forward all permission agreements to the editorial office within five (5) days after signing this Agreement).µÚÈý·½²ÄÁÏ£¬Õâ¸öÎÒûÓÐ Yes No 2. If Contributor answered ¡®Yes¡¯ to any question in Section 2 above, Contributor has explained each answer by providing additional information for each item in the box provided.Yes N/A Èç¹ûÎÒÉÏÃæµÄÈκÎÒ»¸öÎÊÌâÑ¡ÔñÁËyes£¬ÎÒ±£Ö¤¶Ôÿ¸öÎÊÌâ¶¼ÌṩÁËһЩÐÅÏ¢À´ËµÃ÷¡£ÎÒÓ¦¸ÃÑ¡yes°É£¿ For information about the fee-based SAGE Choice publishing option, please visit SAGE's website at: SAGE Choice FAQ. By signing below, Contributors acknowledge their agreement to the above provisions and the terms and conditions stated in the ¡°Terms of the Agreement.¡± Contributors warrant that they have completed all information accurately and thoroughly. By signing this Agreement on behalf of all Contributors, Corresponding Contributor represents and warrants that he/she has received written permission from each Contributor to sign this Agreement on his or her behalf and to grant the exclusive license herein.Õâ¾ä»°µÄÒâ˼ÊDz»ÊÇÔÚÏÂÃæµç×ÓÇ©ÃûÒԺ󣬾ʹú±íÁËͨѶ×÷Õß»ñµÃÁËÿλ×÷ÕßµÄÊéÃæÍ¬Ò⣿ Corresponding Contributor understands that he/she has the option of having each Contributor sign a separate copy of this Agreement by contacting xxµç×ÓÓʼþµØÖ· for a version of this Agreement to be signed by each Contributor and returned directly to the Editorial Office.Õâ¾ä»°µÄÒâ˼ÊDz»ÊÇ¿ÉÒÔͨ¹ý·¢ÓʼþµÄ·½Ê½ÒªÀ´Èô¸ÉͬÒâÊ飬ÈÃÿ¸ö×÷Õßµ¥¶ÀÇ©Ãû£¬ÔÙ·¢»Ø±à¼²¿£¿Õâ¸ö×ö·¨ÊDZØÐëÕâÑù»¹ÊÇ¿ÉÒÔÑ¡ÔñµÄ£¨option£©ÄØ£¿ By Contributor: (to sign this agreement, please enter your name below)ÕâÀïÊDZØÐëÿ¸ö×÷Õß¶¼°Ñ×Ô¼ºµÄÃû×Ö¶¼ÊäÈë½øÈ¥£¬»¹ÊÇÖ»ÒªÊäÈëͨѶ×÷ÕßµÄÃû×Ö£¿ Signed: Õâ Date: ¸÷λսÓÑ£¬±¾È˵ÄÎÊÌâÓеã¶à£¬²»ºÃÒâ˼£¬Ï£Íû´ó¼Ò°ï棬ÔٴθÐл£¡ |
» ²ÂÄãϲ»¶
Çóµ÷¼ÁԺУÐÅÏ¢
ÒѾÓÐ4È˻ظ´
085600²ÄÁÏÓ뻯¹¤306
ÒѾÓÐ4È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑоÀú
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ070300 ѧ˶336Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
286·ÖÈ˹¤ÖÇÄÜרҵÇëÇóµ÷¼ÁÔ¸Òâ¿ç¿¼£¡
ÒѾÓÐ8È˻ظ´
×ÊÔ´Óë»·¾³ µ÷¼ÁÉêÇë(333·Ö)
ÒѾÓÐ5È˻ظ´
280Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
269ר˶Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
²ÄÁÏѧ˶301·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

pxiao08
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 10
- Ìû×Ó: 17
- ÔÚÏß: 6.3Сʱ
- ³æºÅ: 725116
- ×¢²á: 2009-03-17
- ÐÔ±ð: GG
- רҵ: Ðľ³Õϰ¡¢ÐÄÀíÉúÀíÕϰºÍ

2Â¥2013-04-01 10:28:58













»Ø¸´´ËÂ¥